CANbridge Starts Neuromuscular Gene Therapy Program with UMass
publication date: Sep 8, 2020
CANbridge Pharma of Beijing has formed a second gene therapy collaboration with the Horae Gene Therapy Center at the University of Massachusetts Medical School. The latest sponsored research program will develop novel customized adeno-associated virus (AAV) vectors aimed at neuromuscular diseases. The program will be directed by Miguel Sena-Esteves, PhD, Associate Professor of Neurology at the UMass Medical School, Earlier this year, CANbridge formed a collaboration with Guangping Gao, PhD, Director of the Horae Center to study gene therapy-based treatments for rare diseases. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.